The Use of Benzodiazepines and Risk of Incident Type 2 Diabetes in the General Population with Insomnia.
Abstract
Evidence from both cohort analyses and drug target Mendelian randomisation suggests that BDZ use does not significantly increase the risk of T2DM among UK Biobank participants with insomnia.
Key Points
Objective
The aim is to determine whether benzodiazepine use increases the risk of developing type 2 diabetes in individuals with insomnia.
Methods
- Conducted cohort analyses using data from UK Biobank participants.
- Applied Mendelian randomisation to explore drug target effects.
- Evaluated incident type 2 diabetes cases among benzodiazepine users versus non-users.
Results
- No significant increase in type 2 diabetes risk associated with benzodiazepine use was found.
- Findings align across different analytical methods demonstrating consistency in results.